Skip to content
Screener

Eton Pharmaceuticals, Inc. ETON Q1 2026 earnings

Reported May 14, 2026 · After market close

Revenue$24.3MBeat by $2.0M
EPS$0.05Miss by $0.05
Revenue estimate$22.3M
EPS estimate$0.10

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$42.0M
EPS estimate$0.34

Financials

Q1 2026

Income statement

See full
Revenue$24.3M+40.4%
Gross profit$14.7M+49.4%
Operating income$2.4M+614%
Net income$1.6M+199%
EPS (diluted)$0.05+183%

Balance sheet

See full
Cash & equivalents$19.7M+12.9%
Total debt$31.3M+3.7%
Total equity$30.6M+25.2%
Total assets$97.7M+16.3%

Cash flow

See full
Operating cash flow$7.4M+254%
CapEx$75.0K—
Free cash flow$7.3M+251%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$673.38M+93.4%
Enterprise value$684.98M+89.8%
P/S7.7×+0.5×

Profitability

See full
Gross margin54.8%-3.7pp

Returns & leverage

See full
Debt / equity1×-0.2×
Current ratio1.2×-0.8×

FAQ

When did Eton Pharmaceuticals, Inc. report Q1 2026 earnings?
Eton Pharmaceuticals, Inc. (ETON) reported Q1 2026 earnings on May 14, 2026 after market close.
What were Eton Pharmaceuticals, Inc.'s Q1 2026 revenue and EPS?
Eton Pharmaceuticals, Inc. reported revenue of $24.3M and eps of $0.05 for Q1 2026.
Did Eton Pharmaceuticals, Inc. beat estimates in Q1 2026?
Revenue beat the consensus estimate of $22.3M by $2.0M. EPS missed the consensus estimate of $0.10 by $0.05.
How did Eton Pharmaceuticals, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 40.4% from $17.3M a year earlier and eps declined 28.6% from $0.07.
Where can I find Eton Pharmaceuticals, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001437749-26-017063) and the 10-Q periodic report (0001437749-26-017064) directly on SEC EDGAR. The filing index links above go to sec.gov.